Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247078 · ClinicalTrials.gov registry record · Phase 2
The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism
A Phase 2 study of Arachnidism and Latrodectism, sponsored by Instituto Bioclon S.A. de C.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT00247078: Completed Phase 2 study of Arachnidism and Latrodectism, sponsored by Instituto Bioclon S.A. de C.V..
NCT00247078 is a Phase 2 study of Arachnidism and Latrodectism that has completed, run by Instituto Bioclon S.A. de C.V.. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00247078, a Phase 2 study of Arachnidism and Latrodectism, has completed, sponsored by Instituto Bioclon S.A. de C.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the safety and effectiveness of an investigational antivenom and the current standard of care (pain management with opioid analgesics) for treating patients with a widow spider bite. The working hypotheses are as follows: 1. the investigational antivenom is more promptly effective at alleviating the pain associated with a widow spider bite than routine management with opioid pain medication 2. the investigational antivenom is as safe a treatment as opioid pain medication in treating patients with a widow spider bite.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL widow spider antivenom
Study Locations (1)
Colorado
- Denver Health and Hospital Authority - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-10 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00247078 record still lists
NCT00247078 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 2 conditions, with Arachnidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00247078 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT00247078 about?
NCT00247078 is a clinical study titled "The Efficacy and Safety of Aracmyn in Patients With Systemic Latrodectism". The purpose of this study is to compare the safety and effectiveness of an investigational antivenom and the current standard of care (pain management with opioid analgesics) for treating patients with a widow spider bite. The working hypotheses are as follows: 1. the investigational antivenom is m...
What is the current status of trial NCT00247078?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2005-10. Estimated completion is 2006-12.
What conditions does trial NCT00247078 study?
This clinical trial studies the following conditions: Arachnidism, Latrodectism.
What interventions are being tested in trial NCT00247078?
The interventions under investigation include: Placebo (BIOLOGICAL), widow spider antivenom (BIOLOGICAL).
Who is sponsoring clinical trial NCT00247078?
This trial is sponsored by Instituto Bioclon S.A. de C.V., which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00247078 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00247078's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia